The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma
Open accessAbstract
Pancreatic ductal adenocarcinoma (PDAC), one of the most lethal neoplasms, is characterized by an expanded stroma with marked fibrosis (desmoplasia). We previously generated pancreas epithelium-specific TGF-β receptor type II (Tgfbr2) knockout mice in the context of Kras activation (mice referred to herein as Kras+Tgfbr2KO mice) and found that they developed aggressive PDAC that recapitulated the histological manifestations of the human disease. The mouse PDAC tissue showed strong expression of connective tissue growth factor (Ctgf), a profibrotic and tumor-promoting factor, especially in the tumor-stromal border area, suggesting an active tumor-stromal interaction. Here we show that the PDAC cells in Kras+Tgfbr2KO mice secreted much higher levels of several Cxc chemokines compared with mouse pancreatic intraepithelial neoplasia cells, which are preinvasive. The Cxc chemokines induced Ctgf expression in the pancreatic stromal fibroblasts, not in the PDAC cells themselves. Subcutaneous grafting studies revealed that the fibroblasts enhanced growth of PDAC cell allografts, which was attenuated by Cxcr2 inhibition. Moreover, treating the Kras+Tgfbr2KO mice with the CXCR2 inhibitor reduced tumor progression. The decreased tumor progression correlated with reduced Ctgf expression and angiogenesis and increased overall survival. Taken together, our data indicate that tumor-stromal interactions via a Cxcr2-dependent chemokine and Ctgf axis can regulate PDAC progression. Further, our results suggest that inhibiting tumor-stromal interactions might be a promising therapeutic strategy for PDAC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, data from various mouse models indicate that disrupting the CXCR1/2–MDSC axis in tumours is therapeutically efficacious across a wide variety of solid cancers166–172.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [169]
In the citing paper
“Moreover, the important role of CXCR2 in pancreatic adenocarcinoma models (Ijichi et al., 2011) and of S100A8/9 in colorectal cancer (Ichikawa et al., 2011) suggest that the relevance of targeting the CXCL1/2–S100A8/9 axis may extend beyond breast cancer.”
From A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis (2012) · cites this paper as Ijichi et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1256 · Cited by 3,413
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis
Condeelis, J. S., & Pollard, J. W. (2006) · Cell · doi:10.1016/j.cell.2006.01.007 · Cited by 2,677
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
A multigenic program mediating breast cancer metastasis to bone
Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Käkönen, S.-M., Cordon‐Cardo, C., Guise, T. A., & Massagué, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00132-6 · Cited by 2,605
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Self-citationAnalysis of lung tumor initiation and progression using conditional expression of oncogenic K-rasPreprint
Jackson, E. L., Willis, N. A., Mercer, K. L., Bronson, R. T., Crowley, D. G., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,927
Research works printed but not linked: 5
- Rozenblum, 1997, Cancer Res., 57, 1731
- Venkatasubbarao, 2000, Anticancer Res., 20, 43
- Fujioka, 2003, Clin Cancer Res., 9, 346
- Shier, 1999, Anticancer Res., 19, 4969
- Weidner, 1995, Am J Pathol., 147, 9
Cited by
Sorted by citations
Items 101–200 of 256
Naour, A. L., Prat, M., Thibault, B., Mével, R., Lemaitre, L., Leray, H., Joubert, M.-V., Coulson, K., Golzio, M., Lefèvre, L., et al. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz090 · Cited by 58
Myeloid Cell Mediated Immune Suppression in Pancreatic Cancer
Kemp, S. B., di Magliano, M. P., & Crawford, H. C. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.07.006 · Cited by 64
Hosoki, K., Aguilera-Aguirre, L., Brasier, A. R., Kurosky, A., Boldogh, I. R., & Sur, S. A. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2015-0044oc · Cited by 57
Jin, K., Pandey, N. B., & Popel, A. S. (2017) · Oncotarget · doi:10.18632/oncotarget.19417 · Cited by 55
Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals.
Miyabayashi, K., Ijichi, H., Mohri, D., Tada, M., Yamamoto, K., Asaoka, Y., Ikenoue, T., Tateishi, K., Nakai, Y., Isayama, H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1453 · Cited by 57
Self-citationMishra, A., Suman, K. H., Nair, N., Majeed, J., & Tripathi, V. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06648-8 · Cited by 53
CXCR2: a target for pancreatic cancer treatment?
Hertzer, K. M., Donald, G. W., & Hines, O. J. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.772137 · Cited by 53
CXCR2 Macromolecular Complex in Pancreatic Cancer: A Potential Therapeutic Target in Tumor Growth
Wang, S., Wu, Y., Hou, Y., Guan, X., Castelvetere, M. P., Oblak, J. J., Banerjee, S., Filtz, T. M., Sarkar, F. H., Chen, X., et al. (2013) · Translational Oncology · doi:10.1593/tlo.13133 · Cited by 55
Cancer-Associated Fibroblasts’ Functional Heterogeneity in Pancreatic Ductal Adenocarcinoma
Awaji, M. I., & Singh, R. K. (2019) · Cancers · doi:10.3390/cancers11030290 · Cited by 55
Chronic Pancreatitis and the Development of Pancreatic Cancer
Kandikattu, H. K., Venkateshaiah, S. U., & Mishra, A. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200423095700 · Cited by 53
Rajeshkumar, N. V., Yabuuchi, S., Pai, S. G., Tong, Z., Hou, S., Bateman, S., Pierce, D. W., Heise, C. C., Hoff, D. D. V., Maitra, A., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.215 · Cited by 51
Kasashima, H., Yashiro, M., Nakamae, H., Kitayama, K., Masuda, G., Kinoshita, H., Fukuoka, T., Hasegawa, T., Nakane, T., Hino, M., et al. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.07.024 · Cited by 51
Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer
Hamada, S., Masamune, A., & Shimosegawa, T. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00331 · Cited by 49
Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies
Linehan, A., O’Reilly, M., McDermott, R., & O'Kane, G. M. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1369136 · Cited by 57
Inflammation and pancreatic cancer: disease promoter and new therapeutic target
Hamada, S., Masamune, A., & Shimosegawa, T. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0915-x · Cited by 50
Therapeutic effect of c‐Jun N‐terminal kinase inhibition on pancreatic cancer
Takahashi, R., Hirata, Y., Sakitani, K., Nakata, W., Kinoshita, H., Hayakawa, Y., Nakagawa, H., Sakamoto, K., Hikiba, Y., Ijichi, H., et al. (2012) · Cancer Science · doi:10.1111/cas.12080 · Cited by 48
Self-citationTumor-Derived Myeloid Cell Chemoattractants and T Cell Exclusion in Pancreatic Cancer
Vonderheide, R. H., & Bear, A. S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.605619 · Cited by 52
Conditioning solid tumor microenvironment through inflammatory chemokines and S100 family proteins
Nasser, M. W., Elbaz, M., Ahirwar, D. K., & Ganju, R. K. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.05.002 · Cited by 48
Pickup, M. W., Owens, P., Gorska, A. E., Chytil, A. M., Ye, F., Shi, C., Weaver, V. M., Kalluri, R., Moses, H. L., & Novitskiy, S. V. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0311 · Cited by 47
Self-citationEguchi, D., Ikenaga, N., Ohuchida, K., Kozono, S., Cui, L., Fujiwara, K., Fujino, M., Ohtsuka, T., Mizumoto, K., & Tanaka, M. (2012) · Journal of Surgical Research · doi:10.1016/j.jss.2012.06.051 · Cited by 47
Feldkoren, B., Hutchinson, R., Rapoport, Y., Mahajan, A., & Margulis, V. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.03.051 · Cited by 46
Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors
Carvalho, P. D., Machado, A. L., Martins, F., Seruca, R., & Velho, S. (2019) · Cancers · doi:10.3390/cancers11122010 · Cited by 49
Xie, Y., Kuang, W., Wang, D., Yuan, K., & Yang, P. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115175 · Cited by 46
The Clinical Significance and Role of CXCL1 Chemokine in Gastrointestinal Cancers
Korbecki, J., Bosiacki, M., Barczak, K., Łagocka, R., Chlubek, D., & Baranowska‐Bosiacka, I. (2023) · Cells · doi:10.3390/cells12101406 · Cited by 45
Wang, K., Dong, M., Sheng, W., Liu, Q., Yu, D., Dong, Q., Li, Q., & Wang, J. (2015) · Histopathology · doi:10.1111/his.12663 · Cited by 44
Hosoya, H., Kadowaki, K., Matsusaki, M., Cabral, H., Nishihara, H., Ijichi, H., Koike, K., Kataoka, K., Miyazono, K., Akashi, M., et al. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.01.117 · Cited by 42
Self-citationCXCR2 signaling regulates KRAS(G12D)-induced autocrine growth of pancreatic cancer
Purohit, A., Varney, M. L., Rachagani, S., Ouellette, M. M., Batra, S. K., & Singh, R. K. (2016) · Oncotarget · doi:10.18632/oncotarget.6906 · Cited by 42
Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis
Qiu, W., & Su, G. H. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9408-2 · Cited by 45
Kasashima, H., Yashiro, M., Nakamae, H., Masuda, G., Kinoshita, H., Morisaki, T., Fukuoka, T., Hasegawa, T., Nakane, T., Hino, M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178635 · Cited by 41
Kong, X., Li, L., Li, Z., & Xie, K. (2012) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2012.06.006 · Cited by 40
Heparanase and Chemotherapy Synergize to Drive Macrophage Activation and Enhance Tumor Growth
Bhattacharya, U., Gutter-Kapon, L., Kan, T., Boyango, I., Barash, U., Yang, S., Liu, J., Gross-Cohen, M., Sanderson, R. D., Shaked, Y., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1676 · Cited by 40
Nakai, Y., Isayama, H., Ijichi, H., Sasaki, T., Kogure, H., Yagioka, H., Miyabayashi, K., Mizuno, S., Yamamoto, K., Mouri, D., et al. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02311.x · Cited by 40
Self-citationMahat, D. B., Kumra, H., Castro, S. A., Metcalf, E., Nguyen, K. B., Morisue, R., Ho, W. W., Chen, I. X., Sullivan, B., Yim, L., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.06.005 · Cited by 44
Beyond binary: bridging neutrophil diversity to new therapeutic approaches in NSCLC
Horvath, L., Puschmann, C., Scheiber, A., Martowicz, A., Sturm, G., Trajanoski, Z., Wolf, D. G. F., Pircher, A., & Salcher, S. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.01.010 · Cited by 39
Khalafalla, F. G., & Khan, M. W. (2017) · Cancer Growth and Metastasis · doi:10.1177/1179064417709287 · Cited by 37
CXCL2 attenuates osteoblast differentiation by inhibiting the ERK1/2 signaling pathway
Yang, Y., Zhou, X., Li, Y., Chen, A., Liang, W., Liang, G., Huang, B., Li, Q., & Jin, D. (2019) · Journal of Cell Science · doi:10.1242/jcs.230490 · Cited by 37
Blockage of CXCR2 suppresses tumor growth of intrahepatic cholangiocellular carcinoma
Sueoka, H., Hirano, T., Uda, Y., Iimuro, Y., Yamanaka, J., & Fujimoto, J. (2014) · Surgery · doi:10.1016/j.surg.2013.12.037 · Cited by 37
Selitrennik, M., & Lev, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4257 · Cited by 36
Roy, I., Boyle, K. A., Vonderhaar, E. P., Zimmerman, N. P., Gorse, E., Mackinnon, A. C., Hwang, R. F., Franco‐Barraza, J., Cukierman, E., Tsai, S., et al. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2016.146 · Cited by 37
Basso, D., Bozzato, D., Padoan, A., Moz, S., Zambon, C., Fogar, P., Greco, E., Scorzeto, M., Simonato, F., Navaglia, F., et al. (2014) · Cell Communication and Signaling · doi:10.1186/1478-811x-12-20 · Cited by 36
Harnessing the genome for characterization of G‐protein coupled receptors in cancer pathogenesis
Feigin, M. E. (2013) · FEBS Journal · doi:10.1111/febs.12473 · Cited by 36
Saloman, J. L., Albers, K. M., Cruz‐Monserrate, Z., Davis, B. M., Edderkaoui, M., Eibl, G., Epouhe, A. Y., Gedeon, J. Y., Gorelick, F. S., Grippo, P. J., et al. (2019) · Pancreas · doi:10.1097/mpa.0000000000001335 · Cited by 35
Beneforti, L., Dander, E., Bresolin, S., Bueno, C., Acunzo, D., Bertagna, M., Ford, A. M., Gentner, B., Kronnie, G. T., Vergani, P., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16523 · Cited by 37
Host Cxcr2-Dependent Regulation of Pancreatic Cancer Growth, Angiogenesis, and Metastasis
Purohit, A., Saxena, S., Varney, M. L., Prajapati, D. R., Kozel, J. A., Lazenby, A. J., & Singh, R. K. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.01.002 · Cited by 37
Mukai, K., Miyagi, T., Nishio, K., Yokoyama, Y., Yoshioka, T., Saito, Y., Tanaka, S., Shigekawa, M., Nawa, T., Hikita, H., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1402709 · Cited by 35
Prajapati, D. R., Molczyk, C., Purohit, A., Saxena, S., Sturgeon, R., Davé, B. J., Sushil Kumar, K., Batra, S. K., & Singh, R. K. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216185 · Cited by 34
Hill, K. S., Gažiová, I., Harrigal, L. J., Guerra, Y. A., Qiu, S., Sastry, S. K., Arumugam, T., Logsdon, C. D., & Elferink, L. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040420 · Cited by 33
The Gustatory Sensory G-Protein GNAT3 Suppresses Pancreatic Cancer Progression in Mice
Hoffman, M. T., Kemp, S. B., Salas-Escabillas, D. J., Zhang, Y., Steele, N. G., The, S., Long, D., Benitz, S., Wei, Y., Margolskee, R. F., et al. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.08.011 · Cited by 31
Sunami, Y., Häußler, J., Zourelidis, A. A., & Kleeff, J. H. (2022) · Cancers · doi:10.3390/cancers14030744 · Cited by 36
Role of IL-6 in the resolution of pancreatitis in obese mice
Pini, M., Rhodes, D., Castellanos, K. J., Hall, A. R., Cabay, R. J., Chennuri, R., Grady, E. F., & Fantuzzi, G. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.1211627 · Cited by 32
Ion Channels Orchestrate Pancreatic Ductal Adenocarcinoma Progression and Therapy
Hofschröer, V., Najder, K., Rugi, M., Bouazzi, R., Cozzolino, M., Arcangeli, A., Panyi, G., & Schwab, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.586599 · Cited by 33
Human Correlates of Provocative Questions in Pancreatic Pathology
McDonald, O. G., Maitra, A., & Hruban, R. H. (2012) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e318273f998 · Cited by 30
Maeda, S., Kuboki, S., Nojima, H., Shimizu, H., Yoshitomi, H., Furukawa, K., Miyazaki, M., & Ohtsuka, M. (2017) · Cytokine · doi:10.1016/j.cyto.2017.02.007 · Cited by 30
Self-citationInhibiting stromal Class I HDACs curbs pancreatic cancer progression
Liang, G., Oh, T. G., Hah, N., Tiriac, H., Shi, Y., Truitt, M., Antal, C. E., Atkins, A. R., Li, Y., Fraser, C. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42178-6 · Cited by 32
Martínez‐Useros, J., Martin-Galan, M., & García‐Foncillas, J. (2021) · Cancers · doi:10.3390/cancers13020322 · Cited by 29
Metabolic rewiring of pancreatic ductal adenocarcinoma: New routes to follow within the maze
Olivares, O., & Vasseur, S. (2015) · International Journal of Cancer · doi:10.1002/ijc.29501 · Cited by 28
Takikawa, T., Hamada, S., Matsumoto, R., Tanaka, Y., Kataoka, F., Sasaki, A., & Masamune, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169275 · Cited by 28
CXC Chemokine Receptors in the Tumor Microenvironment and an Update of Antagonist Development
Xun, Y., Yang, H., Li, J., Wu, F., & Liu, F. (2020) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/112_2020_35 · Cited by 27
Ota, D., Kanayama, M., Matsui, Y., Ito, K., Maeda, N., Kutomi, G., Hirata, K., Torigoe, T., Sato, N., Takaoka, A., et al. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1183-9 · Cited by 26
Zhou, X., Xiao, F., Sugimoto, H., Li, B., McAndrews, K. M., & Kalluri, R. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2930 · Cited by 23
Recent Advances and Prospects for Multimodality Therapy in Pancreatic Cancer
Chadha, A. S., Khoo, A., Aliru, M. L., Arora, H. K., Gunther, J. R., & Krishnan, S. (2016) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2016.05.002 · Cited by 23
Targeting inflammation in pancreatic cancer: Clinical translation
Steele, C. W., Gill, N. A. K., Jamieson, N. B., & Carter, C. R. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i4.380 · Cited by 23
The function of TRP channels in neutrophil granulocytes
Najder, K., Musset, B., Lindemann, O., Bulk, E., Schwab, A., & Fels, B. (2018) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-018-2146-8 · Cited by 23
Novitskiy, S. V., Forrester, E., Pickup, M. W., Gorska, A. E., Chytil, A. M., Aakre, M. E., Polosukhina, D., Owens, P., Yusupova, D. R., Zhao, Z., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0425-7 · Cited by 22
Self-citationAntitumor and Radiosensitization Effects of a CXCR2 Inhibitor in Nasopharyngeal Carcinoma
Liu, X., Lan, T., Mo, F., Yang, H. J., Wei, Y., & Wei, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.689613 · Cited by 22
Targeting the Stroma in the Management of Pancreatic Cancer
Edwards, P., Kang, B. W., & Chau, I. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.691185 · Cited by 22
Grabliauskaite, K., Saponara, E., Reding, T., Bombardo, M., Seleznik, G. M., Malagola, E., Zabel, A., Faso, C., Sonda, S., & Graf, R. (2015) · The Journal of Pathology · doi:10.1002/path.4666 · Cited by 22
Unfolding innate mechanisms in the cancer microenvironment: The emerging role of the mesenchyme
Koliaraki, V., Henriques, A. R., Prados, A., & Kollias, G. A. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20190457 · Cited by 20
Takahashi, R., Ijichi, H., Sano, M., Miyabayashi, K., Mohri, D., Kim, J., Kimura, G., Nakatsuka, T., Fujiwara, H., Yamamoto, K., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-78320-3 · Cited by 21
Self-citationIjichi, H. (2012) · OncoImmunology · doi:10.4161/onci.19402 · Cited by 19
Self-citationControl of CXCR2 activity through its ubiquitination on K327 residue
Leclair, H. M., Dubois, S. M., Azzi, S., Dwyer, J., Bidère, N., & Gavard, J. (2014) · BMC Cell Biology · doi:10.1186/s12860-014-0038-0 · Cited by 19
Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma
Kimbara, S., & Kondo, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i33.7440 · Cited by 18
Sharma, V., Sachdeva, N. K., Gupta, V., Nada, R., Jacob, J., Sahni, D., & Aggarwal, A. (2022) · Immunobiology · doi:10.1016/j.imbio.2022.152210 · Cited by 17
Myeloid TGF-β signaling contributes to colitis-associated tumorigenesis in mice
Li, J., Liu, Y., Wang, B., Xu, Y., Ma, A., Zhang, F., Ge, C., Yang, Z., Li, J., & Liu, Y. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt172 · Cited by 17
Plac1 Is a Key Regulator of the Inflammatory Response and Immune Tolerance In Mammary Tumorigenesis
Yuan, H., Wang, X., Shi, C., Jin, L., Hu, J., Zhang, A., Li, J., Vijayendra, N., Doodala, V., Weiss, S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24022-w · Cited by 17
Shaw, A. K., Pickup, M. W., Chytil, A. M., Aakre, M. E., Owens, P., Moses, H. L., & Novitskiy, S. V. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117908 · Cited by 17
Self-citationBlocking CTGF-Mediated Tumor–Stroma Interplay in Pancreatic Cancer
Shen, Y., Zhou, Y., Luan, X., & Zhang, W. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.08.005 · Cited by 16
Chemokine Receptor Antagonists: Role in Oncology
Kraus, S. G., Kolman, T., Yeung, A. H., & Deming, D. A. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01117-8 · Cited by 16
Personalized tumor vaccine for pancreatic cancer
Orr, S., Huang, L., Moser, J. A., Stroopinsky, D., Gandarilla, O., Decicco, C., Liegel, J. J., Tacettin, C., Ephraim, A., Cheloni, G., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03237-x · Cited by 16
Freund, E., Spadola, C., Schmidt, A., Privat‐Maldonado, A., Bogaerts, A., von Woedtke, T., Weltmann, K., Heidecke, C.-D., Partecke, L.-I., Käding, A., et al. (2020) · Frontiers in Physics · doi:10.3389/fphy.2020.569618 · Cited by 15
Sharma, V., Aggarwal, A., Jacob, J., & Sahni, D. (2021) · Scandinavian Journal of Immunology · doi:10.1111/sji.13021 · Cited by 15
Targeting Aggressive Fibroblasts to Enhance the Treatment of Pancreatic Cancer
Yu, Y., Schuck, K., Frieß, H., & Kong, B. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1857727 · Cited by 16
Emerging frontiers in pancreatic cancer research
Kumar‐Sinha, C., Wei, I. H., & Simeone, D. M. (2012) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3283567f69 · Cited by 14
Johnson, B. (2023) · Cancers · doi:10.3390/cancers15225484 · Cited by 14
Yamada, T., Tateishi, R., Iwai, M., Tanaka, M., Ijichi, H., Sano, M., Koike, K., & Todo, T. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.12.001 · Cited by 12
Self-citationCXCR2 Inhibition in Pancreatic Cancer: Opportunities for Immunotherapy?
Morton, J. P., & Sansom, O. J. (2016) · Immunotherapy · doi:10.2217/imt-2016-0115 · Cited by 12
CTGF (CCN2): a multifaceted mediator in breast cancer progression and therapeutic targeting
Ghosh, P., Dey, A., Nandi, S., Majumder, R., Das, S., & Mandal, M. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10248-4 · Cited by 11
Advances in immune regulation of the G protein-coupled estrogen receptor
Dong, H., Zeng, X., Xu, J., He, C., Sun, Z., Liu, L., Huang, Y., Sun, Z., Cao, Y., Peng, Z., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112369 · Cited by 10
Shao, S., Delk, N. A., & Jones, C. N. (2024) · Scientific Reports · doi:10.1038/s41598-024-64780-4 · Cited by 11
Kim, S. J., Chang, S., Lee, Y., Kim, N. Y., Hwang, Y., Min, H. J., Yoo, K.-S., Park, E. H., Kim, S., Chung, Y.-H., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.10.056 · Cited by 10
Suri, R., Zimmerman, J. W., & Burkhart, R. A. (2020) · Annals of Pancreatic Cancer · doi:10.21037/apc-20-29 · Cited by 11
Pancreatic biomarkers: Could they be the answer?
Lamarca, Á. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i24.7819 · Cited by 9
Differential Expression of Chemokine Receptors and their Roles in Cancer Imaging
Nimmagadda, S. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00046 · Cited by 9
Seton-Rogers, S. E. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3157 · Cited by 9
High expression of connective tissue growth factor accelerates dissemination of leukaemia
Wells, J. E., Howlett, M., Halse, H. M., Heng, J., Ford, J., Cheung, L. C., Samuels, A. L., Crook, M. L., CHARLES, A. K., Cole, C., et al. (2016) · Oncogene · doi:10.1038/onc.2015.525 · Cited by 9
Chattopadhyay, S., Liao, Y., Wang, X., & Nel, A. E. (2023) · Bioengineering · doi:10.3390/bioengineering10101205 · Cited by 8
Roscigno, G., Jacobs, S., Toledo, B., Borea, R., Russo, G., Pepe, F., Serrano, M. J., Calabrò, V., Troncone, G., Giovannoni, R., et al. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.05.003 · Cited by 9
Qi, Y., Li, C., Du, Y., Lin, J., Li, N., & Yu, Y. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s304261 · Cited by 8
Wu, Q., Yang, C., Rong, L., Li, J., & Lei, L. (2020) · Oncology Letters · doi:10.3892/ol.2020.11877 · Cited by 6
BAG3 Suppresses Loading of Ago2 to IL6 mRNA in Pancreatic Ductal Adenocarcinoma
Li, C. R., An, M., Jiang, J., Yao, H.-B., Li, S., Yan, J. Y., Li, X., & Wang, H. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00225 · Cited by 7
Metadata
- Authors
- Ijichi, H., Chytil, A., Gorska, A. E., Aakre, M. E., Bierie, B., Tada, M., Mohri, D., Miyabayashi, K., Asaoka, Y., Maeda, S., Ikenoue, T., Tateishi, K., Wright, C. V. E., Koike, K., Omata, M., & Moses, H. L.
- Affiliations
- The University of Tokyo (JP)
- Vanderbilt University (US)
- Whitehead Institute for Biomedical Research (US)
- Chiba University (JP)
- Yokohama City University (JP)
- Institute of Medical Science, The University of Tokyo (JP)
- Yamanashi Prefectural Central Hospital (JP)
- Corresponding author
- Ijichi, Hideaki
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2011-10-03
- Volume
- 121
- Issue
- 10
- Pages
- 4106-4117
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3195452
- OpenAlex
- W2014434319
- Cited by
- 256
- References
- 50
- Citations by year
- 2026: 9 · 2025: 8 · 2024: 8 · 2023: 9 · 2022: 13 · 2021: 31 · 2020: 19 · 2019: 17 · 2018: 7 · 2017: 20 · 2016: 20 · 2015: 20 · 2014: 22 · 2013: 27 · 2012: 24
- FWCI
- 11.65
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- Funders
- Vanderbilt University
- Ministry of Education, Culture, Sports, Science and Technology
- Foundation for Promotion of Cancer Research
- National Institutes of Health
- U.S. Public Health Service (U54126505)
- Japan Society for the Promotion of Science (23591011, 22501004)
- National Cancer Institute (CA 085492, R01CA085492, CA102162, R01CA102162)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Connective Tissue Growth Factor Research
- Keywords
- pancreatic ductal adenocarcinoma, tumor-stroma interactions, connective tissue growth factor, CXCR2, CXCL chemokines, desmoplasia, TGFBR2, tumor angiogenesis, tumor growth, overall survival, pancreatic intraepithelial neoplasia
- MeSH terms
- Receptor, Transforming Growth Factor-beta Type II, Animals, Female, Humans, Mice, Inbred C57BL, Mice, Nude, Pancreatic Neoplasms, Signal Transduction, Gene Expression, Proto-Oncogene Proteins p21(ras), Stromal Cells, Protein Serine-Threonine Kinases, Receptors, Transforming Growth Factor beta, Mice, Knockout, Chemokines, CXC, Carcinoma, Pancreatic Ductal, Receptors, Interleukin-8B, Mice, Connective Tissue Growth Factor, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
